IONIS PHARMACEUTICALS INC

IONS - CIK 0000874015

Market cap$12.12 B

Rank#835

SEC filings2,623

IONIS PHARMACEUTICALS INC trades as IONS and has a market capitalization of $12.12 B, making it the #835 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $943.71M, up 33.8% from the prior year and net income of -$381.39M. This page tracks IONIS PHARMACEUTICALS INC through 2,623 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$943.71MFY 2025

Net income (latest FY)-$381.39MFY 2025

Operating cash flow (latest FY)-$268.58MFY 2025

Total assets (latest FY)$3.52BFY 2025

Net margin-40.4%latest FY

Financial performance

Over the last 9 fiscal years IONIS PHARMACEUTICALS INC's revenue grew from $372.78M to $943.71M, a compound annual growth rate of 10.9%. Net profit margin compressed from -16.2% to -40.4% over the same period - every figure below comes from the company's audited annual filings.

IONS annual revenueView details

Key statistics

Market cap: $12.12 B
Share price (derived)market cap / shares outstanding: $73.32
EPS (diluted)FY 2025: $-2.38
Shares outstandingas of 2026-04-23: 0.17B
Total equityas of 2026-03-31: $491.41M
Return on equity: -77.6%
Long-term debtas of 2025-12-31: $1.81B
Cash & equivalentsas of 2026-03-31: $173.38M

Latest filings

Filing	Type	Filed
SCHEDULE 13G/A	-	2026-05-15
Insider trade	4	2026-05-15
SCHEDULE 13G/A	-	2026-05-14
Insider sale notice	144	2026-05-13
Insider trade	4	2026-05-06
Insider trade	4	2026-05-05
Insider sale notice	144	2026-05-04
SCHEDULE 13G	-	2026-04-30

Browse the full filing history (2,623 filings)

Recent press releases

Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study -2026-05-14
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease | Ionis Pharmaceuticals, Inc.
Ionis to host 2026 virtual Annual Meeting of Stockholders2026-05-04
Ionis to host 2026 virtual Annual Meeting of Stockholders | Ionis Pharmaceuticals, Inc.
Ionis to present at upcoming investor conferences2026-05-01
Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
Ionis reports first quarter 2026 financial results and highlights progress on key programs2026-04-29
Ionis reports first quarter 2026 financial results and highlights progress on key programs | Ionis Pharmaceuticals, Inc.
Ionis Partner GSK Announces Bepirovirsen Accepted Priority2026-04-28
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B | Ionis Pharmaceuticals, Inc.

Similar companies

The largest companies sharing IONIS PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T IONS vs LLY

JNJJohnson & Johnson$573.98 B IONS vs JNJ

ABBVAbbVie Inc.$399.47 B IONS vs ABBV

MRKMerck & Co., Inc.$293.16 B IONS vs MRK

AZNAstraZeneca PLC$286.27 B IONS vs AZN

Frequently asked questions

What is IONIS PHARMACEUTICALS INC's market cap?

IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of $12.12 B as of 2026-06-10, ranking #835 among US-listed companies.

How much revenue does IONIS PHARMACEUTICALS INC make?

IONIS PHARMACEUTICALS INC reported revenue of $943.71M for fiscal year 2025, an increase of 33.8% year over year.

Is IONIS PHARMACEUTICALS INC profitable?

In its latest fiscal year IONIS PHARMACEUTICALS INC reported a net loss of $381.39M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.